Dishman Carbogen Amcis Limited (NSE:DCAL)
267.60
+3.85 (1.46%)
Sep 15, 2025, 3:30 PM IST
Dishman Carbogen Amcis Revenue
Dishman Carbogen Amcis had revenue of 7.08B INR in the quarter ending June 30, 2025, with 35.18% growth. This brings the company's revenue in the last twelve months to 28.96B, up 19.85% year-over-year. In the fiscal year ending March 31, 2025, Dishman Carbogen Amcis had annual revenue of 27.12B with 3.66% growth.
Revenue (ttm)
28.96B
Revenue Growth
+19.85%
P/S Ratio
1.43
Revenue / Employee
26.18M
Employees
1,106
Market Cap
41.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 27.12B | 957.30M | 3.66% |
Mar 31, 2024 | 26.16B | 2.03B | 8.41% |
Mar 31, 2023 | 24.13B | 2.72B | 12.72% |
Mar 31, 2022 | 21.41B | 2.29B | 11.96% |
Mar 31, 2021 | 19.12B | -1.32B | -6.44% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Dishman Carbogen Amcis News
- 3 months ago - Dishman Carbogen clears US FDA inspection at Naroda facility with no observations - Business Upturn
- 3 months ago - Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement - Business Upturn
- 4 months ago - Dishman Carbogen Amcis shares surge over 11% as company swings to profit in Q4, EBITDA margin doubles - Business Upturn
- 5 months ago - Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China - Business Upturn
- 5 months ago - Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China - Business Upturn
- 6 months ago - Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance - Business Upturn
- 7 months ago - Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus
- 8 months ago - Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility - Business Upturn